NEW YORK (GenomeWeb News) – Jivan Biologics said yesterday that the US Patent and Trademark Office will re-examine a patent held by Paris-based ExonHit Therapeutics covering methods for identifying differentially spliced gene products.
The patent, No. 6,881,571, is at the center of a patent infringement suit filed last year by ExonHit against Larkspur, Calif.-based Jivan.
Earlier this year, Jivan requested a re-examination of all the claims in the patent on the basis of prior art that it believes was not considered during the original patent examination.
“We expect the patent office to consider whether claims in the ‘571 patent should be amended or invalidated in their entirety,” Jivan CEO Subha Srinivasan said in a statement.